CompX International's 15min chart exhibits bullish signals with KDJ Golden Cross and Marubozu.
PorAinvest
miércoles, 4 de junio de 2025, 11:48 am ET1 min de lectura
CIX--
The KDJ Golden Cross occurs when the K-line crosses above the D-line on the KDJ indicator, signaling a potential bullish trend. The Bullish Marubozu, a candlestick pattern, forms when the body of the candlestick is fully consumed by the previous day's high and low, indicating strong buying pressure. These signals collectively suggest that Compass Therapeutics, Inc. is poised for further upward movement.
The stock price fell by -0.465% on June 3, 2025, from $2.15 to $2.14. However, the technical indicators and recent chart patterns indicate a potential reversal in this downward trend. The stock has shown resilience, with a 1.42% increase over the past two weeks despite a 6.15% fluctuation on the last trading day.
In the short term, the stock is expected to fall by -16.98% over the next three months, with a 90% probability of holding a price between $0.98 and $1.78 at the end of this period. However, if the stock price manages to stay at current levels or higher, the prediction target will adjust positively [1].
The stock has found support from accumulated volume at $2.10, indicating a buying opportunity as an upward reaction can be expected when the support is tested. The stock's volatility, with a daily average of 5.98% over the last week, suggests a high-risk investment. The recommended stop-loss is at $2.06, reflecting the stock's high daily movements and increased risk.
For the upcoming trading day on June 4, 2025, Compass Therapeutics, Inc. is expected to open at $2.17, with a possible trading interval of +/-$0.137 (+/-6.38%) up or down from the last closing price. If the stock takes out the full calculated possible swing range, there will be an estimated 12.76% move between the lowest and highest trading prices during the day.
While Compass Therapeutics, Inc. holds several positive signals, including buy signals from both short and long-term moving averages, the stock is currently considered a hold candidate (hold or accumulate) due to some small weaknesses in the technical picture. The analysis has been downgraded from a buy to a hold/accumulate candidate.
References:
[1] https://stockinvest.us/stock/CMPX
CMPX--
CompX International's 15-minute chart has recently triggered a KDJ Golden Cross and a Bullish Marubozu, which occurred at 11:45 on June 4, 2025. This indicates a shift in the momentum of the stock price towards the upside and suggests potential further growth. As buyers continue to dominate the market, the bullish momentum is likely to persist.
On June 4, 2025, at 11:45, Compass Therapeutics, Inc. (CMPX) stock experienced a significant technical event. The 15-minute chart triggered a KDJ Golden Cross and a Bullish Marubozu, indicating a shift in the stock's momentum towards the upside [1]. This development suggests potential further growth for the stock as buyers continue to dominate the market.The KDJ Golden Cross occurs when the K-line crosses above the D-line on the KDJ indicator, signaling a potential bullish trend. The Bullish Marubozu, a candlestick pattern, forms when the body of the candlestick is fully consumed by the previous day's high and low, indicating strong buying pressure. These signals collectively suggest that Compass Therapeutics, Inc. is poised for further upward movement.
The stock price fell by -0.465% on June 3, 2025, from $2.15 to $2.14. However, the technical indicators and recent chart patterns indicate a potential reversal in this downward trend. The stock has shown resilience, with a 1.42% increase over the past two weeks despite a 6.15% fluctuation on the last trading day.
In the short term, the stock is expected to fall by -16.98% over the next three months, with a 90% probability of holding a price between $0.98 and $1.78 at the end of this period. However, if the stock price manages to stay at current levels or higher, the prediction target will adjust positively [1].
The stock has found support from accumulated volume at $2.10, indicating a buying opportunity as an upward reaction can be expected when the support is tested. The stock's volatility, with a daily average of 5.98% over the last week, suggests a high-risk investment. The recommended stop-loss is at $2.06, reflecting the stock's high daily movements and increased risk.
For the upcoming trading day on June 4, 2025, Compass Therapeutics, Inc. is expected to open at $2.17, with a possible trading interval of +/-$0.137 (+/-6.38%) up or down from the last closing price. If the stock takes out the full calculated possible swing range, there will be an estimated 12.76% move between the lowest and highest trading prices during the day.
While Compass Therapeutics, Inc. holds several positive signals, including buy signals from both short and long-term moving averages, the stock is currently considered a hold candidate (hold or accumulate) due to some small weaknesses in the technical picture. The analysis has been downgraded from a buy to a hold/accumulate candidate.
References:
[1] https://stockinvest.us/stock/CMPX

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios